AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of its Juvéderm VOLUX dermal filler product in China. Juvéderm VOLUX is a hyaluronic acid-based product specifically designed for contouring the lower jaw area. It is used for injection onto the facial periosteum to enhance the mandibular contour in patients with moderate mandibular retrognathia. Clinical studies have demonstrated that the product can maintain clear and sharp jawlines for an extended period of up to 18-24 months. The inclusion of lidocaine in Juvéderm VOLUX helps to reduce patient discomfort during treatment, thereby improving overall treatment comfort.- Flcube.com